Treating Kidney Disease in Patients with APOL1
- Study HIC#:2000030942
- Last Updated:03/01/2024
If you are 18-65 years old, diagnosed with kidney disease, and not diabetic, you may be eligible for a clinical trial that is testing an investigational medication to treat APOL1-Mediated Kidney Disease (AMKD). AMKD is caused by genetic variations, which occur commonly in people with African ancestry, and can increase your risk of reaching end-stage kidney disease. Interested participants will receive investigational genetic testing to see if they carry the disease-causing APOL1 genes. Qualified participants will be compensated for study-related time and reimbursement for travel.
- Age18 years - 60 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Lawrence Ullman Jr.
- Phone Number: 1-203-737-1091
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
If you are 18-65 years old, diagnosed with kidney disease, and not diabetic, you may be eligible for a clinical trial that is testing an investigational medication to treat APOL1-Mediated Kidney Disease (AMKD). AMKD is caused by genetic variations, which occur commonly in people with African ancestry, and can increase your risk of reaching end-stage kidney disease. Interested participants will receive investigational genetic testing to see if they carry the disease-causing APOL1 genes. Qualified participants will be compensated for study-related time and reimbursement for travel.
Eligibility Criteria
Patients must be between the ages of 18 and 65 years (inclusive) and have a BMI of 18.0 to 40.0 kg/m2 and a total body weight ≥ 40kg. Patients must also have an estimated glomerular filtration rate (GFR) between 25-75 mL/min.1.73m2 on Day 1.
Exclusion criteria includes a history of: diabetes, organ transplantation, cancer (except squamous cell skin cancer and basal cell skin cancer, and Stage 0 cervical carcinoma in situ), or positive blood serum for HIV-1 or HIV-2. Additionally, patients who test positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) RNA, or HIV during screening will be excluded.
